Unlocking Full-Spectrum Immunity. Engineering System-Level Defenses Against Refractory Cancer.
Novastra Therapeutics is the pioneer of Next-Generation System-Level
Immune Reprogramming (XIRT).By combining whole-cell antigenicity
with profound innate activation,we overcome the resistance
mechanisms of "Cold" and "Excluded" tumors.
Addressing the
"Immune Desert" Crisis
The first era of Immuno-Oncology mastered the "brakes" (Checkpoint Inhibitors, CPIs). The second era is building "bridges" (Bispecifics). Yet, these therapies fail in the ~80% of patients with "Immune Deserts"—environments where the T-cells required for treatment are simply absent.
We do not rely on pre-existing immune responses; we engineer them. Our OmniAntigen™ Platform (OAP) captures the patient’s entire tumor signature and wraps it in a bio-based nanocloak. This delivers an "Upstream Prime"—generating a polyclonal T-cell army and remodeling the tumor microenvironment to turn deserts into battlefields.
Emerging clinical data demonstrates disease
stabilization and robust immune reactivation
in last-line, advanced, checkpoint-refractory
patients who have exhausted all standard options.
Clinical
Validation
Our proprietary bio-building blocks self-assemble
into a "Zero Leakage" nanocloak. This ensures
potent immunostimulants are delivered
strictly to immune cells, avoiding systemic
toxicity while maximizing potency.
Supramolecular Engineering
An Integrated Global Innovation Engine
enables high-velocity clinical translation,
generating regulatory-compliant data
to accelerate the path to registration.
Integrated Efficiency
